Radiopharmaceuticals and Cold Kits WBAMC
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Army's Medical Readiness Contracting Office - West (MRCO-W) is conducting a Sources Sought / Market Research to identify potential sources capable of providing Radiopharmaceuticals and Cold Kits for William Beaumont Army Medical Center (WBAMC) at Fort Bliss, Texas. This effort involves handling biohazard and radioactive materials for medical use. The Government anticipates a firm fixed-price contract with a 12-month base period and one 12-month option year. Responses are due by May 8, 2026.
Purpose & Scope
This notice is for market research and planning purposes only and does not constitute a solicitation. The Government seeks to identify vendors with the capabilities to supply a detailed list of radiopharmaceutical products, including specific types, quantities, and dosages, as outlined in the 'Required Radiopharmaceuticals WBAMC.pdf' document. This includes products like In-111 Oxyquinoline, Tc-99m Sestamibi UD, and I-123 USP NaI, along with associated services such as Syntrac™ Integration Tools and Nuctract™ Subscription Service Fee.
Key Requirements
Vendors must be able to deliver isotopes between 6:00 a.m. and 5:00 p.m., CST, Monday through Friday, with provisions for after-hour and STAT deliveries. Isotopes must be produced locally due to a shelf-life not exceeding 24 hours, with a contingency for FDG-18 from outside the local area if local production malfunctions. All reagents and radiopharmaceuticals must be FDA approved and compatible with existing Mo99/Tc99m Generators within the hospital.
Specific salient characteristics for Indium-111 oxyquinoline include: diagnostic radiopharmaceutical for radiolabeling autologous leukocytes; supplied as a sterile, non-pyrogenic, isotonic aqueous solution (pH 6.5-7.5); specific composition per ml (37 MBq, 1 mCi of indium in 111, 50 mg oxyquinoline, etc.); radionuclidic impurity limits for indium 114m; and intended for single use only without bacteriostatic agent.
Submission Requirements
Interested vendors shall provide:
- Organization name, physical address, valid POC email, website, telephone number, SAM EUI number, and business size under NAICS 325412.
- Details on capability to perform a contract of this magnitude and complexity, including providing radiopharmaceuticals and cold kits for WBAMC.
- At least three (3) examples of relevant experience.
- Documentation of appropriate products in sufficient detail to demonstrate capability.
Contract & Timeline
- Type: Sources Sought / Market Research (anticipates Firm Fixed-Price)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Set-Aside: None specified
- Response Due: May 8, 2026, 12:00 PM (CST)
- Published: April 24, 2026
- Place of Performance: Fort Bliss, TX
Contact Information
- Primary Point of Contact: Elizabeth Orloski (elizabeth.a.orloski.civ@health.mil)